News & Events

Observations, opinions, and opportunities presented by our experts


Chou Outlines Key Challenges in US Biosimilars Marketplace in STAT News

In a special commentary appearing in STAT News, Jacki Chou, Senior Director, Policy & Economics,  and her co-author discuss overcoming 5 critical challenges in the US biosimilars marketplace, offering some strategic policy recommendations for the consideration of key healthcare stakeholders. […]

JCP Summarizes Baumgardner Study on CAR-T Treatment Cost-Effectiveness

In the latest edition of the Journal of Clinical Pathways (JCP), Zachary Bessette summarizes PHE Senior Research Economist Jim Baumgardner’s recent ASH presentation, focused on studying the cost-effectiveness of novel CAR-T treatments. In the study, Dr. Baumgardner’s team asserts that the introduction of CAR-T therapies represents a major break from the trend of declining incremental effectiveness and provides similar cost-effectiveness to other innovations.


Shafrin in AIS Health: New Medicare Pricing Proposal Could Pose Long-Term Concerns

In the most recent Radar on Specialty Pharmacy, Senior Research Economist Jason Shafrin addresses the Trump Administration’s proposed changes to the International Pricing Index, and how these changes might impact future drug development and innovation.


Load More Posts

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.